Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - Enters into a license agreement with Werfen company Biokit to incorporate Affimer reagents into a Biokit in-vitro diagnostic product. Avacta will receive royalties on future sales of any products brought to market following completion of product development and regulatory approvals. Financial details of the agreement were not disclosed.
"Biokit will develop an automated clinical assay using the Affimer reagents that Avacta has developed for them and I look forward to the successful conclusion of that development process and product launch. There is also potential for the partnership between our two companies to continue and expand to include other diagnostic targets and future Affimer-based IVDs," says Chief Executive Officer Alastair Smith.
Current stock price: 221.00 pence
Year-to-date change: up 94%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Avacta Group (AVCT)